▎药明康德内容团队编辑今日，阿斯利康（AstraZeneca）公司公布了在研口服GLP-1疗法AZD5004，在患有2型糖尿病的肥胖患者中进行的1期临床试验的最新结果。数据显示，这款在研疗法在治疗4周后将患者体重减轻5.8%，并且改善患者的血糖指标。

At the ObesityWeek 2024, AstraZeneca Plc (NASDAQ:AZN) shared data abstracts highlighting early data from AZD5004/ECC5004. In ...

In its presentation at ObesityWeek 2024 meeting in Texas, the multinational drug company AstraZeneca (NASDAQ:AZN) revealed ...

AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...

While expected and seen as largely incremental, Jefferies analyst Peter Welford in a Tuesday note to investors said the detailed data for three early-stage assets support moving them into Phase IIb ...

Follow KT on WhatsApp Channels. The results from the trial gave AstraZeneca confidence to progress the drug into Phase II ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

AstraZeneca’s new obesity pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.

Analyst Sachin Jain from Bank of America Securities maintained a Buy rating on AstraZeneca (AZN – Research Report) and keeping the price ...

AstraZeneca said its experimental weight loss pill was well tolerated by patients in an early-stage clinical trial. The Anglo-Swedish drugmaker’s closely watched weight loss pill, AZD5004 ...

AstraZeneca and Eccogene presented early data from trials on ECC5004 for obesity, showing consistent safety and tolerability. In trials, ECC5004 displayed a linear PK profile and was unaffected by ...

After AstraZeneca (AZN) presented data at the ObesityWeek conference, Deutsche Bank said the company’s oral small molecule GLP1 drug ...